Elevance Health Appoints Amy Schulman as Independent Director

Elevance Health ( (ELV) ) has provided an announcement.

On December 10, 2025, Elevance Health announced the appointment of Amy W. Schulman as an independent director, effective January 12, 2026, with a term expiring at the 2028 annual meeting of shareholders. Schulman, a recognized healthcare executive and governance leader, will serve on the Audit and Finance Committees, bringing her expertise in healthcare innovation and regulatory strategy to the board. This appointment is part of Elevance Health’s strategy to ensure diverse and future-focused leadership, aligning with its long-term goals and stakeholder priorities. Schulman’s addition is expected to enhance the board’s ability to deliver long-term value for shareholders and improve health outcomes.

The most recent analyst rating on (ELV) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Elevance Health stock, see the ELV Stock Forecast page.

Spark’s Take on ELV Stock

According to Spark, TipRanks’ AI Analyst, ELV is a Neutral.

Elevance Health’s overall stock score is driven by strong financial performance and strategic growth initiatives, particularly in the Carelon segment. However, technical indicators suggest potential bearish momentum, and challenges in Medicaid margins and ACA market pressures pose risks. The valuation remains reasonable, providing some investor appeal.

To see Spark’s full report on ELV stock, click here.

More about Elevance Health

Elevance Health is a trusted health partner focused on improving the health of humanity. The company provides a wide range of healthcare solutions, serving 109 million consumers with services in medical, pharmacy, behavioral, clinical, home health, and complex care.

Average Trading Volume: 1,760,620

Technical Sentiment Signal: Sell

Current Market Cap: $73.47B

See more data about ELV stock on TipRanks’ Stock Analysis page.